{{Rsnum
|rsid=3798220
|Gene=LPA
|Chromosome=6
|position=160540105
|Orientation=plus
|GMAF=0.05693
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=LPA
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 0.7 | 17.8 | 81.5
| JPT | 0.9 | 15.9 | 83.2
| YRI | 0.0 | 0.0 | 100.0
| ASW | 1.8 | 3.6 | 94.6
| CHB | 0.7 | 17.8 | 81.5
| CHD | 0.9 | 19.3 | 79.8
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 1.8 | 22.8 | 75.4
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs3798220]], also known as I4399M or Ile4399Met, is a SNP in the apolipoprotein(A) [[LPA]] gene that has been reported to be associated with elevated plasma lipoprotein(a) [Lp(a)] and increased cardiovascular risk, and in particular, [[coronary artery disease]].

In one study, 25,131 initially healthy Caucasian participants in the Women's Health Study were followed for ~10 years. [[rs3798220]](C) allele carriers (3.7%) in the placebo (i.e. not receiving aspirin) group had a 2x higher risk of major cardiovascular events than non-carriers (age-adjusted hazard ratio (HR) of 2.21, CI: 1.39-3.52). Among [[rs3798220]](C) carriers, the risk was reduced more than twofold by [[aspirin]]: for aspirin compared with placebo the age-adjusted HR was 0.44 (CI: 0.20-0.94). The risk was not significantly reduced among non-carriers (age-adjusted HR=0.91, CI: 0.77-1.08). This interaction between carrier status and aspirin allocation was significant (P=0.048). In summary, [[rs3798220]](C) carriers had higher plasma lipoprotein(a) and had double the risk of cardiovascular events, but also benefited more from taking [[aspirin]].{{PMID|18775538|OA=1
}} 

In another study, compared with noncarriers, carriers of the 4399M risk allele (2.7% of controls) had an adjusted odds ratio for severe CAD of 3.14 (CI: 1.51 to 6.56), and had 5-fold higher median plasma lipoprotein(a) levels (P=0.003), leading to the conclusion that the LPA I4399M SNP is associated with severe CAD and plasma lipoprotein(a) levels.{{PMID|17569884}}

{{PMID Auto
|PMID=20032323
|Title=Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
}}

[http://www.marketwatch.com/story/celera-publishes-data-validating-an-increased-risk-of-coronary-heart-disease-in-carriers-of-two-lpa-gene-variants-2010-06-08?reflink=MW_news_stmp celera] says [[rs3798220]] is an independent predictor of risk for 
*[[Coronary Heart Disease]] in men and women
*event reduction from low dose [[aspirin]] therapy in women
Carriers of the rs3798220(C) have higher levels of plasma Lp(a). 

{{PMID Auto
|PMID=20605575
|Title=Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus
}}

{{omim
|id=152200
|rsnum=3798220
}}

{{PMID Auto GWAS
|PMID=21378990
|Trait=None
|Title=Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
|RiskAllele=C
|Pval=3E-11
|OR=1.5100
|ORtxt=[1.33-1.70]
|OA=1
}}

{{PMID Auto
|PMID=22192511
|Title=KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly
}}

{{PMID Auto
|PMID=18682748
|Title=Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction.
|OA=1
}}

{{PMID Auto
|PMID=19060906
|Title=Common variants at 30 loci contribute to polygenic dyslipidemia.
|OA=1
}}

{{PMID Auto
|PMID=19880117
|Title=The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.
}}

{{PMID Auto
|PMID=21252144
|Title=Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
}}

{{PMID Auto
|PMID=21283670
|Title=Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans.
|OA=1
}}

{{PMID Auto
|PMID=22560621
|Title=Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
}}

{{GET Evidence
|gene=LPA
|aa_change=Ile1891Met
|aa_change_short=I1891M
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3798220
|overall_frequency_n=173
|overall_frequency_d=10758
|overall_frequency=0.0160811
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=3
|n_articles_annotated=3
|qualityscore_in_silico=2
|qualitycomment_in_silico=Y
|qualityscore_case_control=2
|qualitycomment_case_control=Y
|qualityscore_severity=2
|qualitycomment_severity=Y
|qualityscore_treatability=4
|nblosum100=-1
|autoscore=2
|n_web_uneval=10
|summary_short=This variant strongly associated with an increase in Lp(a) lipoprotein levels, associated with an increased risk of coronary disease in a dominant or incomplete dominant manner.  This variant is also referred to as I4399M in literature; this discrepancy is due to a highly variable number of kringle repeats in the protein (2-43), our version for inferring amino acid changes from genetic variants uses an assembly with 15 copies.
}}

{{PMID Auto
|PMID=23735648
|Title=Validation and Quantification of Genetic Determinants of Lipoprotein-a Levels and Predictive Value for Angiographic Coronary Artery Disease
}}

{{PMID Auto
|PMID=23978127
|Title=Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention
|OA=1
}}

{{PMID Auto
|PMID=24161338
|Title=Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
}}

{{PMID Auto
|PMID=22898070
|Title=Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.
}}

{{PMID Auto
|PMID=23100282
|Title=Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
|OA=1
}}

{{PMID Auto
|PMID=23278389
|Title=Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene.
}}

{{PMID Auto
|PMID=23375930
|Title=Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.
}}

{{PMID Auto
|PMID=24776095
|Title=LPA rs10455872 polymorphism is associated with coronary lesions in Brazilian patients submitted to coronary angiography
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}